OrbiMed’s Bristol-Myers Squibb BMY Stock Holding History

OrbiMed’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.1M	Buy	925,000 +150,000	+19%	+$8.74M	1.11%	25
2025 Q4	$41.8M	Buy	+775,000	New	+$37.3M	0.85%	37
2023 Q3	–	Sell	-1,488,000	Closed	-$95.2M	–	130
2023 Q2	$95.2M	Sell	1,488,000 -852,000	-36%	-$57.1M	1.72%	15
2023 Q1	$162M	Sell	2,340,000 -244,900	-9%	-$17.3M	3.18%	5
2022 Q4	$186M	Hold	2,584,900	–	–	3.56%	3
2022 Q3	$184K	Buy	2,584,900 +66,200	+3%	+$4.8M	3.41%	2
2022 Q2	$194K	Sell	2,518,700 -89,000	-3%	-$6.78M	3.51%	2
2022 Q1	$190M	Sell	2,607,700 -1,732,100	-40%	-$116M	3.09%	6
2021 Q4	$271M	Sell	4,339,800 -175,600	-4%	-$10.3M	3.48%	2
2021 Q3	$267M	Hold	4,515,400	–	–	2.94%	5
2021 Q2	$302M	Hold	4,515,400	–	–	3.05%	2
2021 Q1	$285M	Buy	4,515,400 +966,300	+27%	+$60.1M	2.67%	8
2020 Q4	$220M	Hold	3,549,100	–	–	1.93%	11
2020 Q3	$214M	Buy	3,549,100 +666,900	+23%	+$40.1M	2.69%	10
2020 Q2	$169M	Buy	2,882,200 +407,400	+16%	+$24.4M	2.39%	13
2020 Q1	$138M	Buy	2,474,800 +774,800	+46%	+$47.4M	2.32%	13
2019 Q4	$109M	Buy	+1,700,000	New	+$97.4M	1.56%	16
2019 Q3	–	Sell	-1,345,200	Closed	-$61M	–	125
2019 Q2	$61M	Buy	1,345,200 +150,200	+13%	+$7M	0.94%	35
2019 Q1	$57M	Buy	1,195,000 +689,100	+136%	+$34.3M	0.88%	35
2018 Q4	$26.3M	Sell	505,900 -1,519,900	-75%	-$81.7M	0.49%	59
2018 Q3	$126M	Sell	2,025,800 -354,500	-15%	-$21M	1.51%	20
2018 Q2	$132M	Sell	2,380,300 -1,295,000	-35%	-$69.9M	1.57%	15
2018 Q1	$232M	Buy	3,675,300 +2,987,300	+434%	+$192M	2.88%	8
2017 Q4	$42.2M	Sell	688,000 -186,700	-21%	-$11.7M	0.53%	58
2017 Q3	$55.8M	Hold	874,700	–	–	0.53%	56
2017 Q2	$48.7M	Sell	874,700 -1,036,300	-54%	-$56.4M	0.51%	57
2017 Q1	$104M	Buy	1,911,000 +417,500	+28%	+$22.9M	1.18%	29
2016 Q4	$87.3M	Sell	1,493,500 -693,900	-32%	-$37.9M	1.11%	31
2016 Q3	$118M	Sell	2,187,400 -2,868,200	-57%	-$184M	1.34%	26
2016 Q2	$372M	Sell	5,055,600 -2,569,300	-34%	-$182M	3.88%	4
2016 Q1	$487M	Sell	7,624,900 -770,100	-9%	-$48.6M	5.13%	1
2015 Q4	$577M	Sell	8,395,000 -273,100	-3%	-$18M	5.23%	1
2015 Q3	$513M	Buy	8,668,100 +917,000	+12%	+$58.2M	5.18%	1
2015 Q2	$516M	Sell	7,751,100 -1,131,700	-13%	-$74.6M	4.31%	2
2015 Q1	$573M	Buy	8,882,800 +1,194,100	+16%	+$74.8M	4.89%	1
2014 Q4	$454M	Buy	7,688,700 +396,700	+5%	+$22.4M	4.34%	2
2014 Q3	$373M	Buy	7,292,000 +103,000	+1%	+$5.14M	3.9%	3
2014 Q2	$349M	Buy	7,189,000 +1,222,600	+20%	+$60.2M	4.09%	2
2014 Q1	$310M	Buy	5,966,400 +501,400	+9%	+$26.7M	3.81%	4
2013 Q4	$290M	Buy	5,465,000 +261,000	+5%	+$13.3M	4.27%	4
2013 Q3	$241M	Buy	5,204,000 +1,882,000	+57%	+$82.6M	4.3%	5
2013 Q2	$148M	Buy	+3,322,000	New	+$144M	3.15%	7

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's BMY Position: Q1 2026 in Review

OrbiMed increased its Bristol-Myers Squibb (BMY) stake by 19% in Q1 2026, buying an estimated $8.74M and bringing the position to 925,000 shares worth $56.1M. The position accounts for 1.11% of the portfolio, ranked #25.

OrbiMed first reported a position in BMY in Q2 2013 and has held it in 42 quarters since. The position peaked at $577M in Q4 2015. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

OrbiMed held 925,000 shares of Bristol-Myers Squibb worth $56.1M as of Q1 2026.
OrbiMed bought 150,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $8.74M.
Bristol-Myers Squibb made up 1.11% of OrbiMed's portfolio in Q1 2026, its #25 holding.
OrbiMed first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 42 quarters since.
OrbiMed's Bristol-Myers Squibb position peaked at $577M in Q4 2015.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.